Human Papilloma Virus (HPV) is a common leather cell virus, mainly by sexual contact, known to have approximately 100 types. Depending on the pathogenicity, it can be divided into low-risk models and high-risk models. The existing research data shows that sustained high-risk HPV infection is considered to be the main cause of cervical cancer, almost all patients with cervical cancer (about 99.7%) can detect high-risk HPV infections, of which about 70% of cervical cancer patients Two high-risk infections from HPV16 with HPV18.
HPV detection can concentrate high-risk populations, and cytology methods can extend the screening interval of HPV and cellular negatives to 3-5 years, while cytology, high-risk HPV positive people need close observation, one year later regular Screening.
At present, the above two methods are still the best strategy for cervical cancer screening. However, with a large number of clinical data reported that HPV detection is more effective than cytological testing, this view is generally recognized. In January 2015, the United States Cathoscope and Cervical Society (ASCCP) and gynecological tumor society (SGO) and other sub-publishing guidelines, high-risk HPV-DNA testing can be used as a pancreatic tool for primary sieve of cervical cancer.
At present, the method of clinically HPV-DNA detection mainly has fluorescent PCR method, hybridized capture method and genetical chip method, etc., cervical cancer screening mainly uses cytology and HPV-DNA to detect two methods.
The company's papillomavirus (HPV) nucleic acid detection tester is used in fluorescent PCR method, using single tube testing, referring to the latest guidelines, covering 18 high-risk gender (16, 18, 26, 31, 33, 35, 39, 45) 51, 52, 53, 56, 58, 59, 66, 68, 73, 82), and can be divided into HPV16, 18 types, and is a HPV detection kit that combines screening and typing detection.
1. Screening of cervical diseases, especially cervical cancer
2. Diversion ASCUS patient
3. Judgment of vaginal mirror indication
4. Evaluation and follow-up of cervical disease
5. Guide the use of HPV vaccines
HPV screening object
1. All women with sexual behavior or more than 21 years old
2. High-risk population (multi-person partners, premature life, HPV / HIV infection, low hygiene conditions / women's conditions / health knowledge lack of women) need to start screening age
3. Women who determine pregnancy
4. Female with HPV vaccine
Tianlong Technology is based on market-oriented, and has been based on the research and development of science and technology, and pursues independent brands.